https://www.selleckchem.com/pr....oducts/gsk2643943a.h
7months vs 16.3months, P=0.159). Inverse probability of treatment weighting-adjusted multivariate Cox proportional hazards analyses showed a significant difference between the pembrolizumab and chemotherapy groups in overall survival (P=0.003, hazard ratio 0.63). Despite the non-negligible age difference between the trial and our clinical practice, our study supports the benefit of second-line pembrolizumab over chemotherapy in real-world practice. Despite the non-negligible age difference between the trial and our clinical practice
Мне нравится
Комментарий
Перепост
